Evidence map›Paper›PMID 32949349›Full record

ArticleEndocrine2021

Hypeprolactinemia: still an insidious diagnosis.

Ludovica Aliberti, Irene Gagliardi, Romolo M Dorizzi, Stefano Pizzicotti, Marta Bondanelli, Maria Chiara Zatelli, Maria Rosaria Ambrosio

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Endocrine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Italian Guidelines for the Management of Prolactinomas.Endocrine, metabolic & immune disorders drug targets · 2023
    Guideline
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Current Insights in Prolactin Signaling and Ovulatory Function.International journal of molecular sciences · 2024
    Review
  8. Review
  9. Article
  10. Hormone Immunoassay Interference: A 2021 Update.Annals of laboratory medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Ludovica AlibertiDepartment of Medical Sciences, Section of Endocrinology and Internal Medicine, University of Ferrara, Ferrara, Italy.
Irene GagliardiDepartment of Medical Sciences, Section of Endocrinology and Internal Medicine, University of Ferrara, Ferrara, Italy.
Romolo M DorizziClinical Pathology Unit, Hub Laboratory, Greater Area, Cesena, Italy.
Stefano PizzicottiLaboratory Division of the S. Anna Hospital, University of Ferrara, Ferrara, Italy.
Marta BondanelliDepartment of Medical Sciences, Section of Endocrinology and Internal Medicine, University of Ferrara, Ferrara, Italy.ORCID 0000-0001-8071-6559
Maria Chiara ZatelliDepartment of Medical Sciences, Section of Endocrinology and Internal Medicine, University of Ferrara, Ferrara, Italy.ORCID 0000-0001-8408-7796
Maria Rosaria AmbrosioDepartment of Medical Sciences, Section of Endocrinology and Internal Medicine, University of Ferrara, Ferrara, Italy. mbrmrs@unife.it.ORCID 0000-0002-7911-9770
University of Ferrara · ITAzienda-Unita' Sanitaria Locale Di Cesena · IT

Funding

Ministero dell'Istruzione, dell'Università e della Ricerca PRIN 2017Z3N3YCUniversità degli Studi di Ferrara FAR2020
6 · The paper itself

Abstract

Hyperprolactinemia can have different causes: physiological, pharmacological, and pathological. When investigating the etiology of hyperprolactinemia, clinicians need to be aware of several conditions leading to misdiagnosis. The most popular pitfalls are: acute physical and psychological stress, macroprolactin, hook effect, even though antibodies interferences and biotine use have to be considered. A 52-year-old woman was referred to Endocrinology clinic for oligomenorrhoea and headache. She worked as a butcher. Hormonal evaluation showed very high PRL (305 ng/ml, reference interval: <24 ng/ml) measured with the ECLIA immunoassay analyzer Elecsys 170. The patient's pituitary MRI was normal and macroprolactin was normal. Hormonal workup showed LH: 71.5 mU/ml (2-10.9 mU/ml), FSH: 111.4 mU/ml (3.9-8.8 mU/ml), Estradiol: 110.7 pg/mL (27-122 pg/ml). Since an interference was suspected, the sample was sent to another laboratory using a different assay. After antibody blocking tubes treatment (Heterophilic Blocking Tube, Scantibodies) PRL was 28.8 ng/ml (reference interval < 29.2 ng/ml). Analytical interference should be suspected when assay results are not consistent with the clinical picture. Endogenous antibodies (EA) include heterophile, human anti-animal, autoimmune and other nonspecific antibodies, and rheumatoid factors, that have structural similarities and can cross-react with the antibodies employed by the immunoassay, causing hyperprolactinemia misdiagnosis. The patient's job (butcher), led us to suspect the presence of anti-animal antibodies. Clinicians should also carefully investigate the use of supplements. Biotin can falsely increase hormone concentration in competitive assays. Many clinicians are still not informed about these pitfalls that are not mentioned in some recent reviews on PRL measurement.

Indexed as

HyperprolactinemiaProlactinAntibodiesDiagnostic ErrorsFemaleHumansImmunoassayMiddle AgedAntibodiesProlactinBiotineHeterophile antibodiesHyperprolactinemiaPitfalls

Identifiers

PMID32949349
PMCPMC8159778
OpenAlexW3087378703

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.